Package Leaflet: Information for the Patient
Vortioxetina Tecnigen 5 mg film-coated tablets EFG
Vortioxetina Tecnigen 10 mg film-coated tablets EFG
Vortioxetina Tecnigen 15 mg film-coated tablets EFG
Vortioxetina Tecnigen 20 mg film-coated tablets EFG
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
Vortioxetina Tecnigen contains the active substance vortioxetine. This belongs to a group of medicines called antidepressants.
Vortioxetine is used to treat episodes of major depression in adults.
Vortioxetine has been shown to reduce a wide range of depressive symptoms, including sadness, inner tension (feeling of anxiety), sleep disturbances (reduced sleep), reduced appetite, difficulty concentrating, feelings of worthlessness, loss of interest in pleasurable activities, feeling of slowness.
Do not take Vortioxetina Tecnigen:
Warnings and precautions
Consult your doctor or pharmacist before starting to take vortioxetine if:
Taking these medicines with vortioxetine may increase the risk of serotonin syndrome. This syndrome can be associated with hallucinations, involuntary jerks, rapid heartbeat, high blood pressure, fever, nausea, and diarrhea.
Your doctor will treat you with caution if you have a history of seizures or unstable/epileptic seizure disorders. Seizures are a potential risk of medicines used to treat depression. Treatment should be discontinued in any patient who experiences seizures or an increase in their frequency.
If you are receiving treatment with antidepressants, including vortioxetine, you may also experience feelings of aggression, agitation, anger, and irritability. If this happens, you should consult your doctor.
Suicidal thoughts and worsening of your depression
If you are depressed and/or suffer from an anxiety disorder, you may sometimes have thoughts of harming or killing yourself. These may increase when you first start taking antidepressants, as all these medicines take time to start working, usually around two weeks, although in some cases it may be longer.
You would be more likely to have these thoughts:
Clinical trial information has shown an increased risk of suicidal behavior in adults under 25 years of age with psychiatric disorders who were treated with an antidepressant.
If at any time you have thoughts of harming or killing yourself, contact your doctor or go directly to a hospital. It may be helpful for you to tell a relative or close friend that you are depressed or have an anxiety disorder and ask them to read this leaflet. You can ask them if they think your depression or anxiety disorder has worsened, or if they are concerned about changes in your attitude.
Children and adolescents
Vortioxetine should not be used in pediatric patients (under 18 years of age) because its efficacy has not been established. The safety of vortioxetine in children and adolescents aged 7 to 17 years is described in section 4.
Other medicines and Vortioxetina Tecnigen
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.
Tell your doctor if you are taking any of the following medicines:
Medicines that increase the risk of seizures:
Please consult your doctor if you are taking any of the medicines mentioned, as your doctor needs to know if you are at risk of having seizures.
If you are given a urine test, taking vortioxetine may cause positive results for methadone when some test methods are used, even if you are not taking methadone. If this happens, a more specific test can be performed.
Taking Vortioxetina Tecnigen with alcohol
It is not recommended to combine this medicine with alcohol.
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor for advice before taking this medicine.
Pregnancy
This medicine should not be used during pregnancy unless your doctor considers it absolutely necessary.
If you take medicines for depression, including vortioxetine, during the last 3 months of pregnancy, you should be aware that the following effects may be seen in the newborn: breathing problems, blue-colored skin, seizures, changes in body temperature, feeding difficulties, vomiting, low blood sugar, stiff or floppy muscles, exaggerated reflexes, tremors, restlessness, irritability, or agitation, lethargy, constant crying, and sleep disturbances. If your baby shows any of these symptoms, contact your doctor immediately.
Make sure your midwife and/or doctor knows you are taking vortioxetine. When taken during pregnancy, especially during the last 3 months, medicines like vortioxetine may increase the risk of a serious disease in the baby called persistent pulmonary hypertension of the newborn (PPHN), making the baby breathe faster and turn blue. These symptoms usually start during the first 24 hours after the baby is born. If this happens to your baby, you should contact your midwife and/or doctor immediately.
If you take this medicine in the final stages of pregnancy, there may be an increased risk of heavy vaginal bleeding shortly after delivery, especially if you have a history of bleeding disorders. Your doctor or midwife should know you are taking this medicine so they can advise you.
Breastfeeding
It is expected that the ingredients of this medicine will pass into breast milk. Vortioxetine should not be used during breastfeeding. Your doctor will decide whether you should stop breastfeeding or stop using vortioxetine, taking into account the benefit of breastfeeding for the child and the benefit of treatment for you.
Driving and using machines
Vortioxetine has little or no influence on the ability to drive or use machines. However, as dizziness has been reported, caution is recommended during these activities when starting treatment with vortioxetine or changing the dose.
Vortioxetina Tecnigen contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per tablet; this is essentially "sodium-free".
Follow exactly the administration instructions of this medicine given by your doctor. In case of doubt, consult your doctor or pharmacist again.
The recommended dose of this medicine is 10 mg of vortioxetine once a day in adults under 65 years of age. Your doctor may increase the dose up to a maximum of 20 mg of vortioxetine per day or reduce it to a minimum of 5 mg of vortioxetine per day, depending on your response to treatment.
For elderly patients 65 years of age or older, the initial dose is 5 mg of vortioxetine once a day.
Method of administration
Take one tablet with a glass of water.
The tablet can be taken with or without food.
Duration of treatment
Take vortioxetine for the time your doctor indicates.
Continue taking vortioxetine even if it takes some time to start feeling better.
You should continue treatment for at least 6 months after feeling better again.
If you take more Vortioxetina Tecnigen than you should
If you take more vortioxetine than you have been told, contact your doctor immediately or go to the nearest hospital emergency department. Take the pack and any remaining tablets with you. Do this even if you feel well. The symptoms in case of overdose are: dizziness, nausea, diarrhea, stomach upset, itching all over the body, drowsiness, and flushing.
After taking doses several times higher than the prescribed dose, seizures (convulsions) and a rare condition called serotonin syndrome have been reported.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medicine and the amount taken.
If you forget to take Vortioxetina Tecnigen
Take the next dose at the usual time. Do not take a double dose to make up for forgotten doses.
If you stop taking Vortioxetina Tecnigen
Do not stop taking vortioxetine without consulting your doctor.
Your doctor may decide to reduce your dose before you stop taking this medicine altogether.
Some patients who have stopped taking vortioxetine have experienced symptoms such as dizziness, headache, sensation of tingling or sensations similar to electric shocks (especially in the head), insomnia, discomfort or nausea, feeling of anxiety, irritability, or agitation, feeling of tiredness or tremors. These symptoms may appear in the first week after stopping this medicine.
If you have any other questions about the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them. The side effects observed were mostly mild or moderate and occurred in the first two weeks of treatment. These effects were usually transient and did not require discontinuation of treatment.
The following side effects have been observed with the frequencies indicated.
Very common: may affect more than 1 in 10 people
Common: may affect up to 1 in 10 people
Uncommon: may affect up to 1 in 100 people
Rare: may affect up to 1 in 1,000 people
Frequency not known: cannot be estimated from the available data
An increased risk of bone fractures has been observed in patients taking this type of medicine.
An increased risk of sexual dysfunction has been reported with the 20 mg dose, and in some patients, this side effect was observed with lower doses.
Other side effects in children and adolescents
The side effects observed with vortioxetine in children and adolescents were similar to those observed in adults, except for abdominal pain-related events, which were observed more frequently in children and adolescents than in adults, and suicidal ideation, which was observed more frequently in adolescents than in adults.
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly through the Spanish Medicines Agency's online platform: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton after "EXP". The expiry date is the last day of the month shown.
This medicine does not require any special storage conditions.
Medicines should not be disposed of via wastewater or household waste. Return any unused medicine to your pharmacist. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Composition of Vortioxetina Tecnigen
Vortioxetina Tecnigen 5 mg film-coated tablets
Vortioxetina Tecnigen 10 mg film-coated tablets
Vortioxetina Tecnigen 15 mg film-coated tablets
Vortioxetina Tecnigen 20 mg film-coated tablets
Product Appearance and Packaging Content
Vortioxetina Tecnigen 5 mg film-coated tablets
Film-coated tablet, pink, round, biconvex with a diameter of 7.0 mm ± 0.2 mm.
Vortioxetina Tecnigen 5 mg film-coated tablets are available in blisters of 14 and 28 tablets.
Only some pack sizes may be marketed.
Vortioxetina Tecnigen 10 mg film-coated tablets
Film-coated tablet, yellow, round, biconvex with a diameter of 7.0 mm ± 0.2 mm.
Vortioxetina Tecnigen 10 mg film-coated tablets are available in blisters of 14 and 28 tablets.
Only some pack sizes may be marketed.
Vortioxetina Tecnigen 15 mg film-coated tablets
Film-coated tablet, orange, round, biconvex with a diameter of 7.0 mm ± 0.2 mm.
Vortioxetina Tecnigen 15 mg film-coated tablets are available in blisters of 14 and 28 tablets.
Only some pack sizes may be marketed.
Vortioxetina Tecnigen 20 mg film-coated tablets
Film-coated tablet, red, round, biconvex with a diameter of 7.0 mm ± 0.2 mm.
Vortioxetina Tecnigen 20 mg film-coated tablets are available in blisters of 14 and 28 tablets.
Only some pack sizes may be marketed.
Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder
Tecnimede España Industria Farmacéutica, S.A.
Avda. de Bruselas, 13, 3º D. Edificio América. Polígono Arroyo de la Vega,
28108 Alcobendas (Madrid)
Spain
Manufacturer
Atlantic Pharma Produções Farmacêuticas, S.A.
Rua De Tapada Grande 2 Abrunheira,
2710-228 Sintra
Portugal
This medicinal productis authorized in the Member States of the European Economic Area under the following names:
Portugal: Vortioxetina Tecnigen 5 mg
Vortioxetina Tecnigen 10 mg
Vortioxetina Tecnigen 15 mg
Vortioxetina Tecnigen 20 mg
Italy: Vortioxetina Tecnigen 5 mg
Vortioxetina Tecnigen 10 mg
Vortioxetina Tecnigen 15 mg
Vortioxetina Tecnigen 20 mg
Spain: Vortioxetina Tecnigen 5 mg film-coated tablets EFG
Vortioxetina Tecnigen 10 mg film-coated tablets EFG
Vortioxetina Tecnigen 15 mg film-coated tablets EFG
Vortioxetina Tecnigen 20 mg film-coated tablets EFG
Date of the last revision of this leaflet: October 2024
Detailed information on this medicinal product is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) (http://www.aemps.gob.es/)